Remove Clinical Trials Remove Organic Chemistry Remove Therapies
article thumbnail

Antibody Drug Conjugates: windows of opportunity

Drug Target Review

These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. Patients and caregivers also assess the benefits offered by different therapies, weighing the progression-free survival with their off-target effects.

article thumbnail

Welcome to new Director David Hulcoop

The Open Targets Blog

After completing my PhD in organic chemistry at the University of Cambridge, I went to Canada as a Leverhulme Trust postdoctoral fellow. These very large teams need to stay on track to hit delivery milestones for clinical trials. Photo credit: Jeff Dowling, EMBL-EBI What is your professional background?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Unlocking the potential of antibody drug conjugates

Drug Target Review

T-DM1, for example, is approved in patients with HER2-positive breast cancer and residual invasive cancer following neoadjuvant therapy. At Zymeworks we apply a holistic approach to optimise each of the ADC components, leveraging insights gained from clinical trials and real-world clinical experience to inform the design of novel ADCs.

Drugs 69
article thumbnail

Marquis Who’s Who Honors David R. Elmaleh, PhD, with Inclusion in Who’s Who in the World

The Pharma Data

A graduate of the Hebrew University of Jerusalem, he earned a Bachelor of Science in chemistry and physics and a Master of Science in physical organic chemistry before completing a Doctor of Philosophy in 1971. and Pure Tech Health. He also remains active as the chief executive officer and chairperson of AZTherapies Inc.

article thumbnail

Women in Stem with Dr Rachel Lagiakos

Drug Target Review

Coupling my desire to be a scientist with my keen sense of adventure, I moved to Alaska out of high school to begin my undergraduate studies in chemistry, applying myself to my STEM classes whilst also climbing mountains and chasing Northern Lights.

article thumbnail

Nixing the Newborn Screening Advisory Committee Is Ill-Advised

PLOS: DNA Science

Adding these two conditions, experts say, would identify 400 to 450 babies a year whose lives could be saved, with gene therapy. That’s the case for some gene therapies. She was integral in pursuing the gene therapy for other families, even though Calliope Joy couldn’t benefit from it. (See